The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain

R. Fass, M (Brian) Fennerty, J. J. Ofman, I. M. Gralnek, C. Johnson, E. Camargo, R. E. Sampliner

Research output: Contribution to journalArticle

331 Citations (Scopus)

Abstract

Background and Aims: Evaluation of new patients with noncardiac chest pain (NCCP) may require a variety of costly tests. The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations. Methods: Thirty-nine patients referred by cardiologists were enrolled. Baseline symptoms were recorded, and the patients were randomized to either placebo or omeprazole (40 mg AM and 20 mg PM) groups for 7 days. Patients were crossed over to the other arm after a washout period and repeat baseline symptom assessment. All patients underwent 24-hour esophageal pH monitoring and upper endoscopy before randomization. Results: Thirty-seven patients (94.9%) completed the study. Twenty-three (62.2%) were classified as GERD positive and 14 as GERD negative. Eighteen (78%) GERD-positive patients and 2 (14%) GERD-negative patients had a positive OT (P <0.01), yielding a sensitivity of 78.3% (95% confidence interval, 61.4-95.1) and specificity of 85.7% (95% confidence interval, 67.4-100). Economic analysis showed that the OT saves $573 per average patient evaluated and results in a 59% reduction in the number of diagnostic procedures. Conclusions: The OT is sensitive and specific for diagnosing GERD in patients with NCCP. This strategy results in significant cost savings and decreased use of diagnostic tests.

Original languageEnglish (US)
Pages (from-to)42-49
Number of pages8
JournalGastroenterology
Volume115
Issue number1
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Omeprazole
Chest Pain
Economics
Gastroesophageal Reflux
Cost Savings
Confidence Intervals
Esophageal pH Monitoring
Symptom Assessment
Random Allocation
Routine Diagnostic Tests
Endoscopy
Placebos

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. / Fass, R.; Fennerty, M (Brian); Ofman, J. J.; Gralnek, I. M.; Johnson, C.; Camargo, E.; Sampliner, R. E.

In: Gastroenterology, Vol. 115, No. 1, 1998, p. 42-49.

Research output: Contribution to journalArticle

Fass, R. ; Fennerty, M (Brian) ; Ofman, J. J. ; Gralnek, I. M. ; Johnson, C. ; Camargo, E. ; Sampliner, R. E. / The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. In: Gastroenterology. 1998 ; Vol. 115, No. 1. pp. 42-49.
@article{96248ba1117248809a45ae3b8503d8c4,
title = "The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain",
abstract = "Background and Aims: Evaluation of new patients with noncardiac chest pain (NCCP) may require a variety of costly tests. The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations. Methods: Thirty-nine patients referred by cardiologists were enrolled. Baseline symptoms were recorded, and the patients were randomized to either placebo or omeprazole (40 mg AM and 20 mg PM) groups for 7 days. Patients were crossed over to the other arm after a washout period and repeat baseline symptom assessment. All patients underwent 24-hour esophageal pH monitoring and upper endoscopy before randomization. Results: Thirty-seven patients (94.9{\%}) completed the study. Twenty-three (62.2{\%}) were classified as GERD positive and 14 as GERD negative. Eighteen (78{\%}) GERD-positive patients and 2 (14{\%}) GERD-negative patients had a positive OT (P <0.01), yielding a sensitivity of 78.3{\%} (95{\%} confidence interval, 61.4-95.1) and specificity of 85.7{\%} (95{\%} confidence interval, 67.4-100). Economic analysis showed that the OT saves $573 per average patient evaluated and results in a 59{\%} reduction in the number of diagnostic procedures. Conclusions: The OT is sensitive and specific for diagnosing GERD in patients with NCCP. This strategy results in significant cost savings and decreased use of diagnostic tests.",
author = "R. Fass and Fennerty, {M (Brian)} and Ofman, {J. J.} and Gralnek, {I. M.} and C. Johnson and E. Camargo and Sampliner, {R. E.}",
year = "1998",
doi = "10.1016/S0016-5085(98)70363-4",
language = "English (US)",
volume = "115",
pages = "42--49",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain

AU - Fass, R.

AU - Fennerty, M (Brian)

AU - Ofman, J. J.

AU - Gralnek, I. M.

AU - Johnson, C.

AU - Camargo, E.

AU - Sampliner, R. E.

PY - 1998

Y1 - 1998

N2 - Background and Aims: Evaluation of new patients with noncardiac chest pain (NCCP) may require a variety of costly tests. The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations. Methods: Thirty-nine patients referred by cardiologists were enrolled. Baseline symptoms were recorded, and the patients were randomized to either placebo or omeprazole (40 mg AM and 20 mg PM) groups for 7 days. Patients were crossed over to the other arm after a washout period and repeat baseline symptom assessment. All patients underwent 24-hour esophageal pH monitoring and upper endoscopy before randomization. Results: Thirty-seven patients (94.9%) completed the study. Twenty-three (62.2%) were classified as GERD positive and 14 as GERD negative. Eighteen (78%) GERD-positive patients and 2 (14%) GERD-negative patients had a positive OT (P <0.01), yielding a sensitivity of 78.3% (95% confidence interval, 61.4-95.1) and specificity of 85.7% (95% confidence interval, 67.4-100). Economic analysis showed that the OT saves $573 per average patient evaluated and results in a 59% reduction in the number of diagnostic procedures. Conclusions: The OT is sensitive and specific for diagnosing GERD in patients with NCCP. This strategy results in significant cost savings and decreased use of diagnostic tests.

AB - Background and Aims: Evaluation of new patients with noncardiac chest pain (NCCP) may require a variety of costly tests. The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations. Methods: Thirty-nine patients referred by cardiologists were enrolled. Baseline symptoms were recorded, and the patients were randomized to either placebo or omeprazole (40 mg AM and 20 mg PM) groups for 7 days. Patients were crossed over to the other arm after a washout period and repeat baseline symptom assessment. All patients underwent 24-hour esophageal pH monitoring and upper endoscopy before randomization. Results: Thirty-seven patients (94.9%) completed the study. Twenty-three (62.2%) were classified as GERD positive and 14 as GERD negative. Eighteen (78%) GERD-positive patients and 2 (14%) GERD-negative patients had a positive OT (P <0.01), yielding a sensitivity of 78.3% (95% confidence interval, 61.4-95.1) and specificity of 85.7% (95% confidence interval, 67.4-100). Economic analysis showed that the OT saves $573 per average patient evaluated and results in a 59% reduction in the number of diagnostic procedures. Conclusions: The OT is sensitive and specific for diagnosing GERD in patients with NCCP. This strategy results in significant cost savings and decreased use of diagnostic tests.

UR - http://www.scopus.com/inward/record.url?scp=0031749344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031749344&partnerID=8YFLogxK

U2 - 10.1016/S0016-5085(98)70363-4

DO - 10.1016/S0016-5085(98)70363-4

M3 - Article

C2 - 9649457

AN - SCOPUS:0031749344

VL - 115

SP - 42

EP - 49

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -